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ABSTRACT
Objective: Parkinson’s disease (PD) is a debilitating age-related neurodegenerative disease characterized by the canonical formation of intracellular 
Lewy bodies comprising α-synuclein protein. Despite the knowledge of factors causing PD, it remains irreversible and incurable. Recent studies have 
highlighted the physiological and pathological involvement of cell cycle proteins in PD. The intriguing relationship between PARK2 and cyclin E which 
leads to upregulation of cyclin E in the absence of functional PARK2 contributes heavily in the onset and progression of PD. The objective of this study 
is to explore neuroprotective action of bimoclomol in attenuating the level of cyclin E and inhibiting post-mitotic cell division led neurodegeneration 
in PD.
Methods: We employed various in silico methods such as drug-likeness parameters, namely, Lipinski filter analysis, Ghose parameters, Veber rules, 
absorption, distribution, metabolism, and excretion - toxicity analysis, pharmacophore based target prediction, active site prediction, and molecular 
docking studies.
Results: The binding of bimoclomol inhibited cyclin E, thereby, attenuating post-mitotic cell division led neurodegeneration in PD.
Conclusion: This study outlines the novel potential of bimoclomol in attenuating cyclin E led neuronal death in PD which may be mediated by heat 
shock proteins (HSP70).
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INTRODUCTION
Parkinson’s disease (PD) is the second most common age-related 
neurodegenerative disorder affecting 2% of population aged above 
65 years in industrialized nations. It is characterized by pathogenic 
protein burden and intracellular inclusion body formation, namely, 
Lewy bodies and Lewy neurites constituted by α-synuclein protein. The 
clinical cardinal features of PD include resting tremor, bradykinesia, 
postural instability and rigor, often accompanied by impaired 
cognition [1]. These symptoms are an outcome of dopaminergic 
neuronal loss in the substantia nigra pars compacta region of the brain.
Genetic and animal studies have outlined various causative phenomenon 
in PD including mutations in genes predominantly; Parkin, α-synuclein, 
PINK1 and DJ-1, oxidative stress, aging, impaired ubiquitin proteasome 
system, and dysfunctional mitochondrial system. Despite the 
availability of this knowledge, the etiology of PD remains incurable and 
irreversible. Moreover, recent studies have highlighted the involvement 
of aberrant cell cycle in PD [2]. Interestingly; cell cycle proteins share a 
very intimate relationship with proteins of PD, physiologically as well as 
pathologically. The PD-associated gene; PINK1 was shown to promote 
cell cycle, and PINK1 deletion reversed cell proliferation [3]. Further, 
the ATM gene responsible for DNA damage response and apoptosis has 
been found to be activated along with retinoblastoma protein leading 
to neuronal death in MPP+ induced PD model [4]. However, the most 
crucial and strong correlation between cell cycle and PD is provided 
by the association of cyclin E and PARK2. Cyclin E is G1/S phase marker 
of the cell cycle and also a substrate of ubiquitin E3 ligase PARK2. 
Mutations associated with loss of functional PARK2 are linked with 
cyclin E enrichment led cell cycle and apoptosis through p53 and Bax 
in PD. Further, mutated PARK2/cyclin E events evoked upregulation 
of Wnt/β catenin and EGFR/AKT signal transduction pathways [5]. This 
intriguing PARK2/cyclin E relation led to speculations that compounds 
which can bind to and attenuate the level of cyclin E can ameliorate 
post-mitotic cell division led neurodegeneration in PD.
Numerous studies have highlighted the neuroprotective action of 
heat shock proteins (HSP) particularly, HSP70. Further, HSP70 is 
closely associated with cell cycle regulation and was also found to 
interact with cyclin E in inclusion body myositis and polymyositis [6]. 
Therefore, we carried out comprehensive data mining for HSP70 
inducers in neurodegenerative diseases and selected bimoclomol 
among 20 compounds based on drug-likeness, pharmacokinetics, 
and blood–brain barrier (BBB) permeability (unpublished results). 
Bimoclomol is a hydroxylamine derivative with molecular formula 
C14H20ClN3O2 and molecular weight of 297.783 g/mol. It has been 
shown to elicit protective effects through induction of HSP27, HSP70, 
and HSP90. Moreover, bimoclomol is currently under Phase II trials in 
amyotrophic lateral sclerosis disease [7]. Therefore, we investigated the 
neuroprotective action of bimoclomol through attenuation of cyclin E in 
PD. Various virtual screening methods such as Lipinski filter, Ghose and 
Veber parameters, pharmacophore modeling based target prediction, 
and ADME analysis were employed to check the efficacy of bimoclomol 
as a neuroprotective agent. Further, we studied the cyclin E inhibiting 
potential of bimoclomol through molecular docking studies.
METHODS
Retrieval of ligand-protein structure
The SDF file of bimoclomol was retrieved from the PubChem database 
(http://www.pubchem.ncbi.nlm.nih.gov/). The pubChem database 
stores physiochemical and biological information of compounds from 
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three different databases. The protein data bank (PDB) file of cyclin E 
was retrieved from PDB (http://www.rcsb.org/pdb/home/home.do).
Drug-likeliness analysis
The drug-likeness of bimoclomol was tested through Lipinski filter 
analysis which is used to test compounds for drug ability. The Lipinski’s 
rule of five is: (a) Molecular mass <500 Dalton, (b) lipophilicity (logP) <5, 
(c) hydrogen bond donors <5, (d) hydrogen bond acceptors <10, 
and (e) molar refractivity between 40 and 130 [8]. In addition, two 
other parameters; Ghose filter and Veber rules were employed 
for drug-likeness screening (www.swissadme.ch/index.php). The 
qualifying parameters of Ghose filter are (a) molecular weight 160-480, 
(b) number of atoms 20-70, (c) molar refractivity 40-130, (d) molar 
refractivity - 0.4-5.6, and (e) polar surface area <140 [9]. The Veber rules 
are (a) rotatable bond count ≤10 and (b) polar surface area ≤140 [10].
Absorption, distribution, metabolism, and excretion - toxicity 
(ADMET) analysis
The toxicity profiling of bimoclomol was carried out through the online 
tool Swiss ADME (www.swissadme.ch/index.php). The Swiss ADME 
tool assessed the ligand on various parameters such as logP, hydrophilic 
nature (logS), and BBB permeability.
Pharmacophore based target prediction
A pharmacophore is a spatial arrangement of steric and electronic 
properties of a compound responsible for its biological response 
against a particular target. Pharmacophore-based target 
prediction of bimoclomol was done with web server PharmMapper 
(http://59.78.96.61/pharmmapper/index.php) [11].
Active site prediction
The active sites of cyclin E were predicted using the pockdrug 
tool (http://pockdrug.rpbs.univ-paris-diderot.fr/cgi-bin/index.
py?page=home) [12]. The PDB structure of cyclin E was uploaded, and 
active sites were predicted using fpocket estimation and setting ligand 
proximity threshold at 5.5.
Preparation of protein and ligand for docking
Cyclin E and bimoclomol were prepared for docking using the online 
docking server (http://www.dockingserver.com/web) [13]. The 
protein was cleaned, and chain A of cyclin E was selected for docking. 
The protein and ligand charge was calculated using Gasteiger method, 
and default solvation parameters were set. The ligand geometry was 
optimized using the MMFF94 method. Further, all non-polar H2 atoms 
were merged, rotatable bonds defined and pH set to 7.0.
Molecular docking
The optimized proteins and ligands were used for molecular docking 
studies using the online docking server (http://www.dockingserver.
com/web). The Autodock tool was used for adding Kollman united 
atom type charges, essential H2 atoms, and solvation parameters. 
Affinity grid maps were generated with 0.375 Å spacing [14]. Further, 
the van der Waals and electrostatic interactions were calculated using 
Autodock parameter set and distance-dependent dielectric functions, 
respectively. Furthermore, the Lamarckian genetic algorithm and Soils 
and Wets local search method was used for docking simulations [15]. 
During docking, all rotatable torsions were dropped. Every docking 
study was arrived after 10 different runs with a cut off energy estimation 
of 250000. Finally, translational step with 0.2 Å, torsion and quaternion 
steps of five were used with a population size of 150.
RESULTS
Protein-ligand structure
The 3D structures of bimoclomol and cyclin E were retrieved from 
docking server and PDB, respectively (Fig. 1).
Screening for drug-likeness and ADMET analysis of compounds
Bimoclomol passed all the parameters related to drug-likeness 
screening, namely, Lipinski, Ghose and Veber. Most importantly, it can 
cross the BBB and has high pharmacokinetics values (Table 1).
Pharmacophore based target prediction
The pharmacophore based target prediction of bimoclomol revealed 
mitogen-activated protein kinase 14 as one of the top 10 targets with a 
fit score of 3.521 and Z-score value of −0.408482 which supported our 
premise of its strong potential in inhibiting cell cycle (Fig. 2).
Active site prediction
Out of top 10 pockets, cyclin E had best pocket at P20 with a drug ability 
score of 0.94 and 0.01 standard deviation (Fig. 3). The volume of given 
pocket was 551.26 cubic angstroms and 14 residues were involved in 
interaction at this site.
Molecular docking of bimoclomol with cyclin E
Bimoclomol bound to cyclin E at P20 pocket and same residues as 
predicted were involved in the interaction (Fig. 4). The estimated free 
energy of binding for cyclin E and bimoclomol was −5.07 kcal/mol, 
and total intermolecular energy was −6.48 kcal/mol (Table 2). There 
were two H2 bond formations involving GLU188 and LYS186 
with bond energies of −0.2603 kcal/mol and −0.2271 kcal/mol, 
respectively. Further, a hydrophobic bond was formed with HIS147 
(−0.6293 kcal/mol).
DISCUSSION
PD is the second most common age-related neurodegenerative disease 
affecting those aged above 60 years. Despite the knowledge of several 
factors which contribute in the occurrence and progression of PD, the 
exact cause and cure remain elusive. Ectopic activation of the cell cycle 
in terminally differentiated neurons is a recently known phenomenon 
which has been shown to drive neurodegeneration through actual DNA 
Fig. 2: Pharmacophore based target prediction of bimoclomol
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synthesis followed by apoptosis [2]. Moreover, PD-associated proteins 
have shared a very intimate relation with cell cycle markers. The G1/S 
phase marker cyclin E is a substrate for PARK2 and participates in 
ubiquitination process. However, mutations in PARK2 led to the loss 
of function thereby, resulting in cyclin E accumulation which in turn, 
activated E2F1 and triggered neuronal death in PD [5]. Thus, it seems 
imperative to design therapeutic strategies aimed at attenuating the 
level of cyclin E to inhibit the cascade of neuronal death in PD.
Various biomolecules such as curcumin elicited HSP70 activity and 
provided protection against neuronal dysfunction, various cancers, and 
in vascular diseases [16-18]. Bimoclomol is a hydroxylamine derivative 
which is nontoxic and elicited its protective effect through HSP 
induction; including HSP70 [19]. HSPs are molecular chaperones which 
are upregulated in the cell to protect it against heat, ROS and hypoxia. 
HSP70 has been shown to promote neuronal survival by mediating the 
activation of pro-survival signaling cascades and through autophagy 
induction [2]. Interestingly, HSP70 has been shown to interact with 
cyclin E in Aβ induced cell cycle re-entry in inclusion body myositis 
and polymyositis [6]. Taken together, all these data provide convincing 
evidence of using HSP70 inducing compound such as bimoclomol 
in attenuating the level of cyclin E and in turn, inhibit the cascade of 
neuronal death in PD.
In this study, we tested the drug-able efficacy of bimoclomol for 
targeting cyclin E in PD. Emphasis was laid on pharmacokinetic analysis 
as aqueous solubility, and dissolution in gastrointestinal fluids are 
defining parameters of in vivo bioavailability of an orally administered 
drug [20]. Similarly, the lipophilicity of a drug directs physiological 
properties such as rate of metabolism, transport across cell membrane 
and interaction with binding sites of the receptor. Further, CNS drugs 
should have logP <4 [21,22]. The logP value for bimoclomol was found 
to be 2.21.
However, the most important property required of a compound 
intended to be a neuroprotective agent is BBB permeability. Bimoclomol 
qualified all the above-mentioned parameters and scored well on 
pharmacokinetics, bioavailability score and could cross the BBB. 
Finally, molecular docking studies indicated that bimoclomol can bind 
to and attenuate the level of cyclin E and possibly, halt or inhibit cell 
cycle re-entry mediated neuronal death in PD. These findings can be 
validated through in vitro and in vivo cell cycle studies in PD.
CONCLUSION
The results of our study provide the novel potential of bimoclomol 
in attenuating the level of cyclin E which has wider implications in 
inhibiting cell cycle re-entry mediated neurodegeneration in PD.
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